Novartis (NVS) said Thursday it has rolled forward its mid-term sales outlook to 2025-2030 with a sales compound annual growth rate of more than 5% to 6%.

The company has also upgraded outlook for its brands, including Kisqali and Scemblix, it said, adding that its mid-term outlook for Kisqali is raised to over $10 billion from more than $8 billion, while Scemblix is raised to over $4 billion from more than $3 billion, previously.

The medicines company said it is "well positioned" for growth beyond 2030.